Invesco Ltd. Lowers Stock Position in Enhabit, Inc. $EHAB

Key Points

• Invesco Ltd. sold 49,367 shares of Enhabit, Inc., reducing its stake by 17.2% to 237,309 shares, valued at approximately $2.08 million.
• Several institutional investors, including D. E. Shaw & Co. and Nuveen Asset Management, have recently increased their holdings in Enhabit, with Nuveen raising its stake by 95.5% in the last quarter.
• UBS Group downgraded Enhabit’s target price from $10.00 to $8.50, maintaining a "neutral" rating, while the stock has a consensus price target of $8.67 according to analysts.

Invesco Ltd. lowered its position in Enhabit, Inc. (NYSE:EHAB - Free Report) by 17.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,309 shares of the company's stock after selling 49,367 shares during the quarter. Invesco Ltd. owned approximately 0.47% of Enhabit worth $2,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Enhabit by 295.2% in the first quarter. GAMMA Investing LLC now owns 3,533 shares of the company's stock worth $31,000 after buying an additional 2,639 shares in the last quarter. Group One Trading LLC boosted its stake in shares of Enhabit by 248.3% during the fourth quarter. Group One Trading LLC now owns 7,746 shares of the company's stock valued at $60,000 after purchasing an additional 5,522 shares during the period. CWM LLC boosted its stake in shares of Enhabit by 383.6% during the first quarter. CWM LLC now owns 11,738 shares of the company's stock valued at $103,000 after purchasing an additional 9,311 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of Enhabit during the fourth quarter valued at approximately $106,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Enhabit during the fourth quarter valued at approximately $110,000.

Insider Transactions at Enhabit

In other news, CFO Ryan Solomon bought 10,000 shares of the company's stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $7.64 per share, with a total value of $76,400.00. Following the completion of the transaction, the chief financial officer owned 193,468 shares of the company's stock, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.40% of the company's stock.

Enhabit Stock Performance

Shares of Enhabit stock traded down $0.03 during trading on Thursday, hitting $7.84. 240,471 shares of the company's stock traded hands, compared to its average volume of 488,239. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.57 and a quick ratio of 1.57. Enhabit, Inc. has a 1 year low of $6.47 and a 1 year high of $10.90. The stock has a market capitalization of $397.16 million, a P/E ratio of -2.93 and a beta of 1.69. The business has a 50-day simple moving average of $7.45 and a 200-day simple moving average of $8.46.

Enhabit (NYSE:EHAB - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.10 by $0.03. The company had revenue of $266.10 million for the quarter, compared to analysts' expectations of $263.39 million. Enhabit had a positive return on equity of 2.72% and a negative net margin of 12.84%. As a group, analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current year.

Wall Street Analyst Weigh In

Separately, UBS Group dropped their price objective on Enhabit from $10.00 to $8.50 and set a "neutral" rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Enhabit presently has a consensus rating of "Hold" and a consensus target price of $8.67.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.